{"title":"Hexokinase II expression is correlated with colorectal cancer prognosis","authors":"Nelson Ho, Brenda L. Coomber","doi":"10.1016/j.ctrc.2016.02.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Enhanced glycolysis is observed during tumorigenesis, with an upregulation in key glycolytic enzymes. Hexokinase II (HKII) catalyzes the first irreversible step of glycolysis and is often overexpressed in tumors. Abnormal vasculature within tumors leads to regional ischemic conditions that promote tumor progression. The aims of this study were to assess the expression of HKII in colorectal cancer tissues, and to correlate HKII expression with clinical parameters and patient outcome.</p></div><div><h3>Materials and method</h3><p>Sections from 60 FFPE primary colorectal cancer tumor samples were dual fluorescence immunostained for HKII and carbonic anhydrase IX (CAIX; serving as an ischemic marker) and assessed using semi-quantitative immunofluorescence. Associations of HKII and CAIX levels with patient characteristics, tumor pathology and clinical outcome were studied using univariate analysis.</p></div><div><h3>Results</h3><p>HKII expression was found in neoplastic cells of non-ischemic regions of tumors and within the tumor stroma. CAIX expression was found primarily in neoplastic cells, and was associated with patient age (OR=4.04, ≥70 <em>vs</em>. <70). Tumor samples scoring lower for HKII were associated with early disease progression (<em>p</em>=0.0155) and poor overall survival (<em>p</em>=0.0248). Interestingly, tumor samples that presented with stromal HKII staining were associated with early disease progression (<em>p</em>=0.0485) and poor overall survival (<em>p</em>=0.0235).</p></div><div><h3>Conclusion</h3><p>We identified low overall HKII expression to be associated with the outcome of colon cancer. However, the correlation between stromal HKII expression and worse survival in colorectal cancer patients warrant further investigation.</p></div><div><h3>MicroAbstract</h3><p>This study assessed the prognostic value of hexokinase II expression in colorectal cancer. In total, 60 FFPE primary colorectal cancer tumor samples were immunostained and correlated with patient characteristics, tumor pathology and clinical outcome. Interestingly, low overall HKII expression was correlated with worse patient outcome. Separately, stromal HKII staining was correlated with worse patient outcome.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2016.02.008","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221308961630010X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14
Abstract
Background
Enhanced glycolysis is observed during tumorigenesis, with an upregulation in key glycolytic enzymes. Hexokinase II (HKII) catalyzes the first irreversible step of glycolysis and is often overexpressed in tumors. Abnormal vasculature within tumors leads to regional ischemic conditions that promote tumor progression. The aims of this study were to assess the expression of HKII in colorectal cancer tissues, and to correlate HKII expression with clinical parameters and patient outcome.
Materials and method
Sections from 60 FFPE primary colorectal cancer tumor samples were dual fluorescence immunostained for HKII and carbonic anhydrase IX (CAIX; serving as an ischemic marker) and assessed using semi-quantitative immunofluorescence. Associations of HKII and CAIX levels with patient characteristics, tumor pathology and clinical outcome were studied using univariate analysis.
Results
HKII expression was found in neoplastic cells of non-ischemic regions of tumors and within the tumor stroma. CAIX expression was found primarily in neoplastic cells, and was associated with patient age (OR=4.04, ≥70 vs. <70). Tumor samples scoring lower for HKII were associated with early disease progression (p=0.0155) and poor overall survival (p=0.0248). Interestingly, tumor samples that presented with stromal HKII staining were associated with early disease progression (p=0.0485) and poor overall survival (p=0.0235).
Conclusion
We identified low overall HKII expression to be associated with the outcome of colon cancer. However, the correlation between stromal HKII expression and worse survival in colorectal cancer patients warrant further investigation.
MicroAbstract
This study assessed the prognostic value of hexokinase II expression in colorectal cancer. In total, 60 FFPE primary colorectal cancer tumor samples were immunostained and correlated with patient characteristics, tumor pathology and clinical outcome. Interestingly, low overall HKII expression was correlated with worse patient outcome. Separately, stromal HKII staining was correlated with worse patient outcome.
背景:在肿瘤发生过程中,糖酵解作用增强,关键的糖酵解酶表达上调。己糖激酶II (HKII)催化糖酵解的第一个不可逆步骤,在肿瘤中经常过度表达。肿瘤内的血管异常导致局部缺血,促进肿瘤进展。本研究的目的是评估HKII在结直肠癌组织中的表达,并将HKII表达与临床参数和患者预后联系起来。材料和方法对60例FFPE原发性结直肠癌肿瘤切片进行HKII和碳酸酐酶IX (CAIX;作为缺血标志物),并使用半定量免疫荧光进行评估。采用单因素分析研究HKII和CAIX水平与患者特征、肿瘤病理和临床结果的关系。结果shkii在肿瘤非缺血区肿瘤细胞及肿瘤间质中均有表达。CAIX主要在肿瘤细胞中表达,且与患者年龄相关(OR=4.04,≥70 vs. <70)。HKII评分较低的肿瘤样本与早期疾病进展(p=0.0155)和较差的总生存期(p=0.0248)相关。有趣的是,间质HKII染色的肿瘤样本与早期疾病进展(p=0.0485)和较差的总生存期(p=0.0235)相关。结论:HKII总体低表达与结肠癌的预后相关。然而,间质HKII表达与结直肠癌患者较差生存率之间的相关性值得进一步研究。摘要本研究评估己糖激酶II在结直肠癌中的表达对预后的价值。共60例FFPE原发性结直肠癌肿瘤样本进行免疫染色,并与患者特征、肿瘤病理和临床结局相关。有趣的是,总体HKII表达较低与患者预后较差相关。另外,间质HKII染色与患者预后较差相关。